Multiple Myeloma Market Analysis

Drug Class (Proteasome Inhibitors, Immunomodulatory Drugs, Steroids, Monoclonal Antibodies)

The immunomodulatory drugs segment is expected to hold 38% share multiple myeloma market during the forecast period. Oral immunomodulators are recognised as a new therapy and are believed to be extremely successful in enhancing the course of treatment for a number of tumours. The immunomodulators category consequently controlled a disproportionately high part of the global market due to these drugs' strong revenue positions. For instance, 2,625 new cases of multiple myeloma are expected to be diagnosed in Australia in 2022, according to data given by Cancer Australia. The same source also claims that a person's chance of receiving a multiple myeloma diagnosis by the time they are 85 years old is 1 in 111, or 0.90 percent.

Distribution Channel (Hospital, Retail, Online Pharmacies)

The hospital segment is expected to hold around 45% share of the global multiple myeloma market during the forecast period. Generally, the medicine used to treat this condition can, at least once a year, be recommended and given in hospital settings. This will make it possible to follow treatment guidance in multiple myeloma and also the proper administration of life-saving therapeutics. These factors are leading the hospital segment for multiple myeloma treatment market.

Our in-depth analysis of the global market includes the following segments:

Drug Class	Proteasome Inhibitors Immunomodulatory Drugs Monoclonal Antibodies Steroids
Therapy	Immunotherapy Chemotherapy Radiation Therapy Stem Cell Transplant
Distribution Channel	Hospital Retail Online Pharmacies

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of multiple myeloma is assessed at USD 32.36 billion.

The multiple myeloma market size was over USD 28.89 billion in 2024 and is poised to reach USD 178.71 billion by the end of 2037, growing at around 14.8% CAGR during the forecast period i.e., between 2025-2037. Growing incidences of multiple myeloma, growing number of product unveilings and increase in the initiatives taken by the government will drive the market growth.

North America industry is holding the largest share of about 33% by 2037, owing to increasing demand for the treatment and implementation of advanced therapeutics in the region.

The major players in the market include Bristol-Myers Squibb Company, Amgen Inc., Johnson & Johnson, Novartis AG, Sanofi, Janssen Pharmaceuticals Inc., Genentech, Inc., AbbVie Inc., Karyopharm.

Multiple Myeloma Market Analysis